重新利用代谢药物作为抗炎药物
Andrew E Hogan1, Cian Davis2, Benjamin J Jenkins3
1Kathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth, Co Kildare, Ireland.
Trends in endocrinology and metabolism: TEM
|August 14, 2025
概括
像GLP-1疗法和SGLT2抑制剂这样的新代谢药物表现出超越减肥的抗炎作用. 这些疗法可能为治疗慢性炎症提供新的途径,而不依赖于它们的代谢效益.
科学领域:
- 代谢和炎症医学 代谢和炎症医学
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
背景情况:
- 体重和代谢失调与慢性炎症密切相关.
- 基于葡萄糖类-1 (GLP-1) 的疗法和糖共运输体2 (SGLT2) 抑制剂已成为代谢障碍的成功治疗方法.
- 新出现的证据表明,这些药物具有抗炎性质,可能超出其代谢作用.
研究的目的:
- 审查代谢药物对炎症伴随性疾病的影响.
- 探索这些药物的抗炎作用背后的分子机制.
- 讨论代谢药物作为直接抗炎药物的潜在重新用途.
主要方法:
- 对代谢药物和炎症研究的文献综述.
- 对参与药物诱导的抗炎作用的分子通路的分析.
- 讨论临床证据和潜在的治疗应用.
主要成果:
- 基于GLP-1的疗法和SGLT2抑制剂显示出显著的抗炎作用.
- 这些效应似乎部分独立于代谢参数的改善.
- 涉及到特定的分子机制,例如调节细胞因子的产生和免疫细胞活动.
结论:
- 代谢药物,包括GLP-1疗法和SGLT2抑制剂,具有显著的抗炎能力.
- 它们的抗炎作用可能为炎症状况提供新的治疗策略.
- 需要进一步研究将这些药物重新用于直接抗炎使用是有必要的.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203
Inflammatory Bowel Disease IV: Pharmacological Management
189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
189
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
232
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
232
Drug Biotransformation: Overview
2.9K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.9K
Drugs for Treatment of Ulcerative Colitis in IBD
237
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
237


